# US 2013/0157980 A1 · Substituted indole derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157980 A1
- Document ID: US20130157980A1
- Status: Published application
- Kind: A1
- Application number: 13/471,512
- Filed: 2012-05-15
- Published: 2013-06-20
- Earliest claimed: 2011-05-17
- Assignees: Novartis AG
- Inventors: Nigel Graham COOKE; Rita RAMOS; Karen KAMMERTOENS; Maurice VAN EIS
- Web page: https://patentgrep.com/patent/US20130157980A1

## CPC

- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to substituted indole derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

## Claims

### Claim 1

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof,
Wherein
X is CH or N;
R is H or PO3H2;
R1 is H; or C1-4alkyl;
R2 is H; or C1-4alkyl;
R3 is H; C1-4alkyl; CN; Hal; or OH; and
R4 and R5 are independently from each other H, or C1-4alkyl; or R4 and R5 form together with the carbon atom to which they are attached a 3-6 membered cycloalkyl group.

### Claim 2 (depends on 1)

The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof,
wherein X is CH;
R is H;
R1 is H;
R2 is H; or C1-4alkyl;
R3 is H; or C1-4alkyl; and
R4 and R5 are independently from each other H; or R4 and R5 form together with the carbon atom to which they are attached a 3-6 membered cycloalkyl group.

### Claim 3 (depends on 1)

The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or hydrate thereof,
wherein X is N;
R is PO3H2;
R1 is H;
R2 is H; or C1-4alkyl;
R3 is H; and
R4 and R5 are independently from each other H; or R4 and R5 form together with the carbon atom to which they are attached a 3-6 membered cycloalkyl group.

### Claim 4 (depends on 1)

The compound according to claim 1 which is a compound of formula (III)
or a pharmaceutically acceptable salt or hydrate thereof.

### Claim 5 (depends on 1)

The compound in accordance to claim 1, which is phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl]ester, mono-hydrate.

### Claim 6 (depends on 1)

The compound in accordance to claim 1, which is 3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-1-hydroxymethyl-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound in accordance to claim 1, which is phosphoric acid mono-{3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl}ester or a pharmaceutically acceptable salt thereof.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

Method for the treatment or prevention of a disease or condition in which PKC activation plays a role or is implicated, in particular in a subject in need thereof which comprises administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or hydrate thereof.

### Claim 10 (depends on 9)

The method for treatment according to claim 9, wherein said treatment or prevention may be mediated by T lymphocytes, B lymphocytes, mast cells, eosinophils or cardiomyocytes, and hence may be indicated in acute or chronic rejection of organ or tissue allo- or xenografts, graft-versus-host disease, host-versus-graft disease, atheriosclerosis, cerebral infarction, vascular occlusion due to vascular injury such as angioplasty, restenosis, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, hypertension, heart failure, chronic obstructive pulmonary disease, CNS disease such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious disease such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock, or traumatic shock.

### Claim 11 (depends on 9)

The method for treatment according to claim 9, wherein said treatment or prevention addresses acute or chronic rejection of organ or tissue allo- or xenografts, graft-versus-host disease, host-versus-graft disease, multiple sclerosis, psoriasis, or rheumatoid arthritis.

### Claim 12 (depends on 1)

A combination, comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt or hydrate thereof, and a second drug substance.

### Claim 13

A crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl]ester, which has an X-ray powder diffraction pattern with at least one of the following peaks at an angle of refraction 2 theta (θ) of 9.525, 16.356, 17.091, 18.005, 20.859, each ±0.2, especially as depicted in FIG. 1 and/or Table 1.

### Claim 14 (depends on 1)

A method of manufacturing a compound of formula (I) as defined in claim 1,
wherein X is CH or N;
R is H or PO3H2;
R1 is H; or C1-4alkyl;
R2 is H; or C1-4alkyl;
R3 is H; C1-4alkyl; CN; Hal; or OH; and
R4 and R5 are independently from each other H, or C1-4alkyl; or R4 and R5 form together with the carbon atom to which they are attached a 3-6 membered cycloalkyl group, comprising:
(a) optionally, for compounds wherein R1 and/or R2 are hydrogen, treating the maleimide of formula (Va) with di-tert-butyl dicarbonate in the presence or absence of a solvent such as THF or dichloromethane and/or a base such as triethyl amine, thereby yielding the maleimide of formula (Va) comprising tert-butoxycarbonyl groups instead of the hydrogens on R1 and/or R2 where appropriate;
(b) treating the optionally protected maleimide of formula (Va) with formaldehyde in the presence or absence of a solvent and/or a base such as potassium, thereby yielding an alcohol of formula (Vb), wherein R═H;
(c) optionally treating the alcohol of formula (Vb) with trichloroacetonitrile typically in the presence of a base, to form a reactive ester, followed by the treatment with a phosphorylating agent, typically in the presence of a base, whereupon the resulting intermediate ester is treated with an appropriate acid, in the absence of presence of a solvent to yield the final product in accordance to general formula (I), or as an alternative step (c) alcohol of formula (Vb) may be reacted directly with a phosphoric acid ester, under Mitsunobu reaction conditions to furnish the phosphoric acid ester, which may then be hydrolyzed, to furnish the final product of formula (I).

### Claim 15 (depends on 13)

The crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl]ester, according to claim 13, in the form of the mono-hydrate, which has an X-ray powder diffraction pattern with at least one of the following peaks at an angle of refraction 2 theta (θ) of 9.525, 16.356, 17.091, 18.005, 20.859, each ±0.2, especially as depicted in FIG. 1 and/or Table 1.

### Claim 16 (depends on 13)

The crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl]ester, according to claim 13, which has an X-ray powder diffraction pattern with at least three of the following peaks at an angle of refraction 2 theta (θ) of 9.525, 16.356, 17.091, 18.005, 20.859, each ±0.2, especially as depicted in FIG. 1 and/or Table 1.

### Claim 17 (depends on 13)

The crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl]ester, according to claim 13, which has an X-ray powder diffraction pattern with all the following peaks at an angle of refraction 2 theta (θ) of 9.525, 16.356, 17.091, 18.005, 20.859, each ±0.2, especially as depicted in FIG. 1 and/or Table 1.
